High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial

Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel

(2022) Hartmut Döhner et al.   BLOOD

High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study

(2022) Jun Li et al.   Blood Cancer Journal

3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?

(2021) Kenny Tang et al.   Current Oncology Reports

Targeting MCL-1 in hematologic malignancies: Rationale and progress

(2020) AndrewH. Wei et al.   BLOOD REVIEWS

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

(2020) Eytan M. Stein et al.   BLOOD

Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-κB repressing factor

(2019) Xin-Jie Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges

(2019) Rory M. Shallis et al.   BLOOD REVIEWS

Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial

(2018) Anna Candoni et al.   AMERICAN JOURNAL OF HEMATOLOGY

Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD

(2018) Richard F. Schlenk et al.   BLOOD

Cytarabine and daunorubicin for the treatment of acute myeloid leukemia

(2017) Tracy Murphy et al.   EXPERT OPINION ON PHARMACOTHERAPY

Methods of Detection of Measurable Residual Disease in AML

(2017) Yi Zhou et al.   Current Hematologic Malignancy Reports

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia

(2016) Lesley J. Scott   DRUGS

‘Acute myeloid leukemia: a comprehensive review and 2016 update’

(2016) I De Kouchkovsky et al.   Blood Cancer Journal

Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients

(2015) M. Libura et al.   BLOOD

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

(2015) H. Dombret et al.   BLOOD

Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia

(2015) C. Song et al.   BLOOD

Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study

(2015) Thomas Prebet et al.   BRITISH JOURNAL OF HAEMATOLOGY

Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature Review

(2015) Erik Hefti et al.   Cardiovascular Toxicology

A Phase I Study of Midostaurin and Azacitidine in Relapsed and Elderly AML Patients

(2015) Brenda W. Cooper et al.   Clinical Lymphoma Myeloma & Leukemia

Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia

(2015) C Song et al.   LEUKEMIA

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study

(2015) Courtney D DiNardo et al.   Lancet Haematology

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia

(2013) S. Nand et al.   BLOOD

Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial

(2013) Jie Jin et al.   LANCET ONCOLOGY

U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia

(2013) F. Alvandi et al.   ONCOLOGIST

RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia

(2012) J. Aimiuwu et al.   BLOOD

Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study

(2012) Jerzy Holowiecki et al.   JOURNAL OF CLINICAL ONCOLOGY

Performance comparison of exome DNA sequencing technologies

(2011) Michael J Clark et al.   NATURE BIOTECHNOLOGY

Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells

(2008) Hongyan Tong et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and β-catenin

(2008) Junya Kuroda et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY